Geva, M., Drill, E., Grieve, C., Okwali, M., Boardman, A., Caron, P., Ghione, P., Berning, P., Hamlin, P., Owens, C., David, K., Horwitz, S., Kumar, A., Noy, A., Moskowitz, A., Luttwak, E., Palomba, L., Epstein-Peterson, Z., Steiner, R., Stuver, R., Torka, P., Johnson, W., Zain, J., Intlekofer, A., Dogan, A., Vardhana, S., Riley, R., Reese, D., Chron, A., Henshaw, L., Lue, J., Zelenetz, A., Salles, G., Falchi, L. (2025). Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need. Blood. https://doi.org/10.1182/blood-2025-2756